IMMUNITYBIO, INC.

Analyst Reco. ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX Other stock markets 11:02:09 2024-06-10 am EDT			5-day change	1st Jan Change
6.195 ^USD	+1.56%		+0.56%	+24.20%

May. 09	ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	May. 06	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	May. 03	MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	Apr. 30	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	Apr. 29	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	Apr. 29	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	Mar. 25	MT
Piper Sandler Downgrades ImmunityBio to Neutral From Overweight, Cuts Price Target to $4 From $10	23-05-12	MT
Jefferies Starts ImmunityBio at Buy With $8 Price Target	22-08-03	MT
Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating	22-05-31	MT
ImmunityBio : Says Phase 2/3 Trial in BCG-Unresponsive Bladder Cancer Patients Achieves Complete Response Rate of 72%	21-09-13	MT
ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial	21-09-13	CI
Nantkwest : Reports Positive Interim Data on Survival Rates from Pivotal Pancreatic Cancer Trials; Shares Hit New 52-Week High	21-01-14	MT
NantKwest, Inc. and ImmunityBio, Inc. Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials	21-01-13	CI
ImmunityBio, Inc. Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate	20-12-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer